Tert-butyl-[1-(5-methyl-4-oxo-3-pyridin-3-ylquinazolin-2-yl)ethyl]carbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Tert-butyl-[1-(5-methyl-4-oxo-3-pyridin-3-ylquinazolin-2-yl)ethyl]carbamic acid
• 英文别名: tert-butyl-[1-(5-methyl-4-oxo-3-pyridin-3-ylquinazolin-2-yl)ethyl]carbamic acid
• 化学式: C₂₁H₂₄N₄O₃
• 分子量: 380.4
• InChiKey: GSKHUVDXAHEFLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  86.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Evarts Jerry

  公开号：US20150218154A1

  公开（公告）日：2015-08-06

  The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R 1 , R 2 , n, R 3 , R 4 , R 5 and R 6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3Kδ. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3Kδ.

  本公开提供式(I)的磷脂酰肌醇3-激酶（PI3K）抑制剂，或其药学上可接受的盐，其中R1、R2、n、R3、R4、R5和R6如本文所定义。这些化合物可用于治疗由一个或多个PI3K异构体介导的疾病，例如PI3Kδ。本公开还提供包括式(I)的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗由一个或多个PI3K异构体介导的疾病，例如PI3Kδ的方法。
• SUBSTITUTED PYRIMIDINE AMINOALKYL-QUINAZOLONES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：Gilead Calistoga LLC

  公开号：EP2941426A1

  公开（公告）日：2015-11-11
• US9266878B2
  申请人：——

  公开号：US9266878B2

  公开（公告）日：2016-02-23
• [EN] SUBSTITUTED PYRIMIDINE AMINOALKYL-QUINAZOLONES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS<br/>[FR] PYRIMIDINE AMINOALKYL-QUINAZOLONES SUBSTITUÉES EN TANT QU'INHIBITEURS DE PHOSPHATIDYLINOSITOL 3-KINASE
  申请人：GILEAD CALISTOGA LLC

  公开号：WO2014100765A1

  公开（公告）日：2014-06-26

  The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which R1, R2, n, R3, R4, R5 and R6 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3Kδ. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3Kδ.